Compare JOE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | WVE |
|---|---|---|
| Founded | 1936 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | N/A | 2015 |
| Metric | JOE | WVE |
|---|---|---|
| Price | $65.49 | $13.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $29.94 |
| AVG Volume (30 Days) | 209.9K | ★ 4.1M |
| Earning Date | 02-25-2026 | 03-03-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 53.79 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $488,689,000.00 | $109,230,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.20 |
| P/E Ratio | $36.34 | ★ N/A |
| Revenue Growth | 26.89 | ★ 103.75 |
| 52 Week Low | $40.19 | $5.28 |
| 52 Week High | $66.08 | $21.73 |
| Indicator | JOE | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 68.04 | 45.52 |
| Support Level | $63.55 | $13.72 |
| Resistance Level | $65.75 | $15.97 |
| Average True Range (ATR) | 1.62 | 1.33 |
| MACD | 0.36 | -0.54 |
| Stochastic Oscillator | 91.70 | 5.62 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.